EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer

Takuya Tsujino iD, Satoshi Tokushige, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Takaya Ohno, Keita Nakamori, Ryoichi Maenosono und 15 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Takuya Tsujino und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan. Hauptthemen laut MEDLINE: Abiraterone Acetate, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Suzuken Memorial Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is little evidence of abiraterone acetate (AA) plus prednisone for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC). In this study, we conducted a comparative analysis of real‐world survival outcomes between AA plus prednisone and enzalutamide (Enz) in patients with nmCRPC, utilizing our consortium dataset. Materials and Methods The clinical records of 133 nmCRPC patients treated with first‐line Enz or AA plus prednisone were analyzed. The primary endpoints of the study were overall survival (OS) and cancer‐specific survival (CSS). Cumulative incidence function (CIF) using Fine and Gray models was also utilized to assess non‐cancer‐caused death considering the competing risk of cancer‐caused death.

Results

During a median follow‐up of 36 months, 34 patients (25.6%) had deceased, with a median OS of 99 months in the entire cohort. There were no significant differences in comorbidities between the Enz and AA groups. Time to PSA progression (TTPP: HR 0.81, 95% CI 0.51–1.30, P = 0.375) and CSS (HR 1.32, 95% CI 0.55–3.44, P = 0.5141) were comparable between the two groups. However, intriguingly, there was a trend towards shorter OS in patients treated with AA plus prednisone compared to Enz (HR 0.57, 95% CI 0.29–1.12, P = 0.0978, median of 99 and 69 months in Enz and AA groups, respectively). CIF analysis revealed that nmCRPC patients treated with AA plus prednisone were more likely to result in non‐cancer‐caused death than those treated with Enz (HR 5.22, 95% CI 1.88–14.50, P = 0.0014).

Conclusions

Our real‐world survival analysis suggests that while AA plus prednisone may demonstrate comparable treatment efficacy to Enz in the context of nmCRPC, there may be an increased risk of non‐cancer‐caused death. Physicians should take into consideration this information when making treatment decisions for patients with nmCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abiraterone AcetateProstatic Neoplasms, Castration-ResistantMaleHumansPrednisonePhenylthiohydantoinTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsBenzamidesNitriles

Stichwörter der Autor:innen

abiraterone acetateandrogen receptor signaling inhibitorcastration-resistant prostate cancerenzalutamidenonmetastatic castration-resistant prostate cancer

Substanzen

Abiraterone AcetatePrednisonePhenylthiohydantoinenzalutamideBenzamidesNitriles

Autor:innen und Institutionen

  • Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Department of Urology, The Jikei University School of Medicine, Minato-ku, Japan.
  • Department of Urology, Tokyo Medical University, Shinjuku-ku, Japan.
  • Department of Urology, Fujita-Health University School of Medicine, Toyoake, Japan.

ORCID-Profile: Takuya Tsujino, Fumihiko Urabe

Förderung

  • Japan Society for the Promotion of Science
  • Suzuken Memorial Foundation

Zitieren

APA

Tsujino, T., Tokushige, S., Komura, K., Fukuokaya, W., Adachi, T., Hirasawa, Y., Hashimoto, T., Yoshizawa, A., Saruta, M., Ohno, T., Nakamori, K., Maenosono, R., Nishimura, K., Yamazaki, S., Uchimoto, T., Yanagisawa, T., Mori, K., Urabe, F., Tsuzuki, S., …, & Azuma, H. (2023). Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer. Cancer Medicine. https://doi.org/10.1002/cam4.6536

Vancouver

Tsujino T, Tokushige S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, et al. Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer. Cancer Medicine. 2023. doi:10.1002/cam4.6536

BibTeX
@article{Tsujino2023,
  author = {Tsujino, Takuya and Tokushige, Satoshi and Komura, Kazumasa and Fukuokaya, Wataru and Adachi, Takahiro and Hirasawa, Yosuke and Hashimoto, Takeshi and Yoshizawa, Atsuhiko and Saruta, Masanobu and Ohno, Takaya and Nakamori, Keita and Maenosono, Ryoichi and Nishimura, Kazuki and Yamazaki, Shogo and Uchimoto, Taizo and Yanagisawa, Takafumi and Mori, Keiichiro and Urabe, Fumihiko and Tsuzuki, Shunsuke and Iwatani, Kosuke and Yamamoto, Shutaro and Takahara, Kiyoshi and Inamoto, Teruo and Kimura, Takahiro and Ohno, Yoshio and Shiroki, Ryoichi and Azuma, Haruhito},
  title = {Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6536}
}
Kostenlos starten →